Without a specialized delivery technology (which is still being researched), a simple spray may not actually get the medicine into your bloodstream
#CaringforLife #CiplaAt90 To view or add a comment, sign in Cipla launches Yurpeak (tirzepatide), a one-weekly injectable therapy for managing obesity and type 2 diabetes mellitus (T2DM) two of the countrys most pressing health challenges
Rhythm Pharmaceuticals Setmelanotide Setmelanotide, an Melanocortin-4 Receptor (MC4R) agonists designed to treat hyperphagia and severe obesity , is approved by the US FDA to reduce excess body weight and maintain weight reduction long term in adult and pediatric patients 2 years of age and older with syndromic or monogenic obesity due to Bardet-Biedl syndrome (BBS) or genetically confirmed pro-opiomelanocortin (POMC), including proprotein convertase subtilisin/kexin type 1 (PCSK1), deficiency or leptin receptor (LEPR) deficiency
A separate randomized trial found that combining semaglutide with metformin outperformed metformin alone producing greater weight loss, improved insulin sensitivity, better cycle regularity, and higher rates of natural pregnancy
Preclinical studies suggest GLP-1 agonists may reduce synovial macrophage infiltration and decrease production of matrix metalloproteinasesenzymes responsible for cartilage degradation in RA
These results show that adding supervised exercise during GLP-1 use improves weight loss maintenance after treatment termination
